Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$31.23
$31.23
$3.61
$31.25
$8.32B1.188.78 million shs40 shs
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$0.81
+1.3%
$0.90
$0.61
$6.80
$44.82M1.22292,016 shs87,143 shs
uniQure N.V. stock logo
QURE
uniQure
$14.49
+1.4%
$14.54
$3.76
$19.18
$789.87M0.081.97 million shs328,148 shs
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$15.00
+1.1%
$16.72
$7.93
$25.29
$1.33B0.721.62 million shs663,493 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00%0.00%0.00%0.00%0.00%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
0.00%+3.15%-17.19%+20.00%-77.62%
uniQure N.V. stock logo
QURE
uniQure
0.00%+4.51%-12.79%+61.66%+270.46%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
0.00%+1.56%+1.90%+0.07%+88.92%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
N/AN/AN/AN/AN/AN/AN/AN/A
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
3.4529 of 5 stars
3.54.00.00.00.03.30.6
uniQure N.V. stock logo
QURE
uniQure
1.9636 of 5 stars
3.51.00.00.00.92.50.6
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
3.1784 of 5 stars
4.43.00.00.01.80.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00
N/AN/AN/A
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
3.00
Buy$4.50455.56% Upside
uniQure N.V. stock logo
QURE
uniQure
2.91
Moderate Buy$37.82161.09% Upside
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.87
Moderate Buy$32.14114.29% Upside

Current Analyst Ratings Breakdown

Latest TVTX, IMGN, PRLD, and QURE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$30.00
6/11/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$30.00
6/11/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$35.00 ➝ $32.00
5/30/2025
uniQure N.V. stock logo
QURE
uniQure
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$38.00
5/29/2025
uniQure N.V. stock logo
QURE
uniQure
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$70.00
5/19/2025
uniQure N.V. stock logo
QURE
uniQure
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/16/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/16/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$30.00 ➝ $30.00
5/12/2025
uniQure N.V. stock logo
QURE
uniQure
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
5/12/2025
uniQure N.V. stock logo
QURE
uniQure
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
5/6/2025
uniQure N.V. stock logo
QURE
uniQure
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$287.61M28.91N/AN/A$0.71 per share43.99
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$7M6.53N/AN/A$2.39 per share0.34
uniQure N.V. stock logo
QURE
uniQure
$27.12M29.26N/AN/A($0.14) per share-103.46
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$233.18M5.71N/AN/A$0.76 per share19.74
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
-$222.93M-$0.31N/A84.41N/A-25.56%-22.11%-13.53%N/A
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$127.17M-$1.69N/AN/AN/AN/A-89.18%-69.26%8/11/2025 (Estimated)
uniQure N.V. stock logo
QURE
uniQure
-$239.56M-$4.39N/AN/AN/A-1,077.05%-483.87%-34.28%8/7/2025 (Estimated)
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$321.55M-$2.81N/AN/AN/A-82.88%-1,179.73%-41.10%7/30/2025 (Estimated)

Latest TVTX, IMGN, PRLD, and QURE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
uniQure N.V. stock logo
QURE
uniQure
-$1.07-$0.82+$0.25-$0.82$5.93 million$1.57 million
5/6/2025Q1 2025
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$0.47-$0.42+$0.05-$0.42N/AN/A
5/1/2025Q1 2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$0.55-$0.47+$0.08-$0.47$77.44 million$81.73 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
N/AN/AN/AN/AN/A
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
N/AN/AN/AN/AN/A
uniQure N.V. stock logo
QURE
uniQure
N/AN/AN/AN/AN/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.13
5.70
5.65
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
N/A
5.18
5.18
uniQure N.V. stock logo
QURE
uniQure
1.53
11.99
11.99
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
9.46
2.05
2.03

Institutional Ownership

CompanyInstitutional Ownership
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
90.50%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
79.72%
uniQure N.V. stock logo
QURE
uniQure
78.83%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
5.07%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
63.90%
uniQure N.V. stock logo
QURE
uniQure
4.79%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
4.19%
CompanyEmployeesShares OutstandingFree FloatOptionable
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
277266.26 million252.76 millionOptionable
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
12056.46 million20.38 millionOptionable
uniQure N.V. stock logo
QURE
uniQure
50054.78 million52.15 millionOptionable
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
46088.81 million85.08 millionOptionable

Recent News About These Companies

Q2 EPS Estimate for Travere Therapeutics Lowered by Analyst
Q2 EPS Estimate for Travere Therapeutics Cut by Analyst

New MarketBeat Followers Over Time

Media Sentiment Over Time

ImmunoGen stock logo

ImmunoGen NASDAQ:IMGN

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

Prelude Therapeutics stock logo

Prelude Therapeutics NASDAQ:PRLD

$0.81 +0.01 (+1.25%)
As of 07/3/2025 02:45 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

uniQure stock logo

uniQure NASDAQ:QURE

$14.48 +0.21 (+1.44%)
Closing price 07/3/2025 03:51 PM Eastern
Extended Trading
$14.50 +0.02 (+0.13%)
As of 07/3/2025 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Travere Therapeutics stock logo

Travere Therapeutics NASDAQ:TVTX

$15.00 +0.16 (+1.08%)
Closing price 07/3/2025 01:04 PM Eastern
Extended Trading
$15.00 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.